In addition to direct cytotoxicity, romidepsin can cause a wide range of immune changes like other HDAC inhibitors through the expression of costimulatory molecules (PD-L1), MHC, tumor antigens and cytokines [11–14]. The gene discussed is CD274; the disease is neoplasm.